PRLD Prelude Therapeutics Incorporated
Financings ·
Prelude Therapeutics gave Incyte an option on its preclinical JAK2V617F JH2 inhibitor program for a $35 million cash payment, plus a $25 million stock purchase. Exercising the option would cost Incyte $100 million, and the company is pausing a separate SMARCA2 degrader program.
Nasdaq told Prelude on September 18, 2025 that the bid-price matter is closed. The company had been out of compliance since a March 27, 2025 notice.
Prelude Therapeutics Incorporated is a precision oncology company that discovers and develops novel precision cancer medicines for underserved patients. It creates new chemical entities against clinically validated targets in areas of high unmet need, using modalities such as targeted protein degradation. Its pipeline includes kinase programs, targeted protein degraders and precision antibody drug conjugates. Since its inception in 2016, the company says it has received clearance from the FDA for multiple investigational new drug applications and has advanced several programs into clinical trials. It works with partner AbCellera Biologics, Inc. on an early-stage discovery program involving potent degraders as payloads for novel antibodies that target tumor specific antigens. The company also has other proprietary programs in various stages of preclinical development. Its approach focuses on molecules with broad mechanisms that have multiple links to oncogenic driver pathways in select patients, with the aim of serving patients who have limited or no treatment options.
| Product or program | What it is | Stage |
|---|---|---|
| Degrader payloads with AbCellera | Potent degraders as payloads for antibodies against tumor-specific antigens | early-stage discovery |
| Kinase programs | Precision oncology kinase programs in the pipeline | |
| Precision antibody drug conjugates | Antibody drug conjugate programs in the pipeline |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $12.1 million | $7.0 million |
| Research and development | $94.3 million | $118.0 million |
| Net income (loss) | -$99.5 million | -$127.2 million |
| Cash from operations | -$56.3 million | -$102.9 million |
| Cash and equivalents | $35.3 million | $12.5 million |
| Short-term investments | $68.0 million | $121.1 million |
Prelude Therapeutics Incorporated trades under the ticker PRLD on NASDAQ.
Prelude Therapeutics Incorporated is listed on NASDAQ.
The SEC Central Index Key (CIK) for Prelude Therapeutics Incorporated is 1678660. Its filings are on SEC EDGAR.
79,803,485 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Prelude Therapeutics Incorporated under United States.
Our directory classifies Prelude Therapeutics Incorporated as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Prelude Therapeutics Incorporated is US74065P1012.
aibio.space lists Prelude Therapeutics Incorporated among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Prelude Therapeutics Incorporated is a precision oncology company that discovers and develops novel precision cancer medicines for underserved patients. It creates new chemical entities against clinically validated targets in areas of high unmet need, using modalities such as targeted protein degradation.
Degrader payloads with AbCellera: Potent degraders as payloads for antibodies against tumor-specific antigens Stage: early-stage discovery.
Kinase programs: Precision oncology kinase programs in the pipeline Stage: not stated in text.
$12.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Prelude Therapeutics Incorporated reported a net loss of $99.5 million for the fiscal year ended Dec 31, 2025, and used $56.3 million of cash in operations, per its annual report to the SEC.
$94.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio